Surgical Science Sweden AB (SUS) — Capital Reinvestment Ratio
Surgical Science Sweden AB (SUS) has a Capital Reinvestment Ratio of 0.27x as of March 2026, meaning it reinvests 0% of its operating cash flow (Skr65.31 Million) in capital expenditures (Skr17.96 Million). Check SUS intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Surgical Science Sweden AB Capital Reinvestment Ratio (2015–2025)
This chart tracks Surgical Science Sweden AB's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see how efficiently does Surgical Science Sweden AB generate cash.
Annual Capital Reinvestment Ratio for Surgical Science Sweden AB (2015–2025)
Year-by-year Capital Reinvestment Ratio for Surgical Science Sweden AB from 2015 to 2025. See SUS cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (SEK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | Skr79.80 Million | Skr11.68 Million | ▼ -57.7% |
| 2024 | 0.35x | Skr137.22 Million | Skr47.53 Million | ▲ +87.0% |
| 2023 | 0.19x | Skr238.29 Million | Skr44.13 Million | ▼ -30.6% |
| 2022 | 0.27x | Skr129.49 Million | Skr34.55 Million | ▼ -27.5% |
| 2021 | 0.37x | Skr39.08 Million | Skr14.38 Million | ▼ -1.7% |
| 2020 | 0.37x | Skr23.23 Million | Skr8.69 Million | ▲ +131.8% |
| 2019 | 0.16x | Skr55.20 Million | Skr8.91 Million | ▼ -87.1% |
| 2018 | 1.26x | Skr6.88 Million | Skr8.64 Million | ▼ -17.7% |
| 2017 | 1.53x | Skr7.94 Million | Skr12.12 Million | ▲ +74.8% |
| 2016 | 0.87x | Skr13.40 Million | Skr11.70 Million | ▼ -21.1% |
| 2015 | 1.11x | Skr7.50 Million | Skr8.30 Million | — |